The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 24, 2007
Filed:
Aug. 02, 2001
Zohar Yakhini, Yaacov, IL;
Michael Bittner, Rockville, MD (US);
Jeff Trent, Rockville, MD (US);
Amir Ben-dor, Bellevue, WA (US);
Paul Meltzer, Rockville, MD (US);
Yidong Chen, Rockville, MD (US);
Ashani Weeraratna, Owings Mil, MD (US);
Yuan Jiang, Gaithersburg, MD (US);
Nick Sampas, San Jose, CA (US);
Edward Dougherty, College Station, TX (US);
Zohar Yakhini, Yaacov, IL;
Michael Bittner, Rockville, MD (US);
Jeff Trent, Rockville, MD (US);
Amir Ben-Dor, Bellevue, WA (US);
Paul Meltzer, Rockville, MD (US);
Yidong Chen, Rockville, MD (US);
Ashani Weeraratna, Owings Mil, MD (US);
Yuan Jiang, Gaithersburg, MD (US);
Nick Sampas, San Jose, CA (US);
Edward Dougherty, College Station, TX (US);
Agilent Technologies, Inc., Santa Clara, CA (US);
Abstract
The overexpression of certain marker genes including Wnt5a has been found useful in the identification of more aggressive forms of malignant melanoma. Therefore, the overexpression of these genes in tumor samples of malignant melanoma may be useful in the diagnosis, profiling, and treatment of patients suffering from this disease. Inhibitors of Wnt5a activity may be useful in the treatment of aggressive forms of malignant melanoma. Inhibition of Wnt5a activity may be effected by any method including anti-sense therapy, gene therapy, and pharmaceutical intervention.